Neratinib (HKI-272)

DRUG2 trials

Sponsors

Puma Biotechnology, Inc., Hebei Medical University Fourth Hospital

Conditions

HER2-positive Breast CancerHepatic Insufficiency

Phase 1

Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease

CompletedNCT00781430

Puma Biotechnology, Inc.Hepatic Insufficiency

Start: 2009-04-30End: 2010-02-28Updated: 2012-05-14

Unknown Phase

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

Not yet recruitingNCT07019272

Hebei Medical University Fourth HospitalHER2-positive Breast Cancer

Start: 2025-06-30End: 2030-10-31Target: 170Updated: 2025-06-13